Sandra P. D’Angelo

18.6k citations

191 papers · 7.8k indexed · 4 hit papers · h-index 37

Impact in

Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Polyomavirus and related diseases
- Vascular Tumors and Angiosarcomas
Pulmonary and Respiratory Medicine top 0.5%
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations

Papers in

Oncology 150
- CAR-T cell therapy research 63
- Cancer Immunotherapy and Biomarkers 37
- Polyomavirus and related diseases 30
- Vascular Tumors and Angiosarcomas 25
Pulmonary and Respiratory Medicine 98
- Sarcoma Diagnosis and Treatment 71

Co-authors: William D. Tap Mark A. Dickson Gary K. Schwartz Cristina R. Antonescu Richard D. Carvajal Mark G. Kris Célèste Lebbé Mary Louise Keohan
Journals: Journal of Clinical Oncology (93 papers)Annals of Oncology (8 papers)Journal for ImmunoTherapy of Cancer (7 papers)Clinical Cancer Research (4 papers)American Society of Clinical Oncology Educational Book (4 papers)
Partner nations: United States France Germany

In The Last Decade

Sandra P. D’Angelo

181 papers receiving 7.6k citations

Hit Papers

align trajectories log scale

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials 2018 · 494 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 The Lancet Oncology
2016 The Lancet Oncology
2015 Journal of Clinical Oncology
2012 Clinical Cancer Research

Peers

Countries citing papers authored by Sandra P. D’Angelo

Since Specialization

Citations

This map shows the geographic impact of Sandra P. D’Angelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra P. D’Angelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra P. D’Angelo more than expected).

Fields of papers citing papers by Sandra P. D’Angelo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra P. D’Angelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra P. D’Angelo. The network helps show where Sandra P. D’Angelo may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sandra P. D’Angelo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sandra P. D’Angelo Line = papers co-authored together Sandra P. D’Angelo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma Journal of Clinical Oncology ·Sandra P. D’Angelo, Mihaela Druta, Brian A. Van Tine, David A. Liebner, Scott M. Schuetze, William D. Tap, Н. Ю. Курепина, 赵川兵, Feiyan Chen, Gurpreet S. Kapoor, Sunil Suchindran, Stefan Zajic, Dylan Alexander Sherman, Milushka Miroslava Quezada-Márquez, Jaegil Kim, M. Ronald, Ellie Corigliano, Ioanna Eleftheriadou, Michael J. Nathenson, Neeta Somaiah	2025	8
2	1752P A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma Annals of Oncology ·О А Соколова, Vishkurti Marsida, Ciara M. Kelly, K. Karátson, Mary Louise Keohan, Anna Hedre, Juan L. Córdova-Otero, Jason E. Chan, Damon R. Reed, Mrinal M. Gounder, Yaoyao Jia, Ping Chi, M. Dickson, Catherine A. T. Susch, Sandra P. D’Angelo, Sujana Movva	2024	1
3	1720MO A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma Annals of Oncology ·Vishkurti Marsida, 尹五榮, Mark A. Dickson, Sujana Movva, Ciara M. Kelly, Jason E. Chan, Ping Chi, Anna Hedre, Mary Louise Keohan, Mrinal M. Gounder, Robert G. Maki, Jordynn Farrar, Isabelle Guionet-Hertier, K. Karátson, Joseph P. Erinjeri, Robert A. Lefkowitz, C Antonescu, Samuel Singer, William D. Tap, Sandra P. D’Angelo	2024	4
4	Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma Clinical Cancer Research ·Sandra P. D’Angelo, Célèste Lebbé, Paul Nghiem, Andrew S. Brohl, 王起津, 郭湛君, Kravchenko I.V., 朱丹青, Parantu K. Shah	2024	8
5	Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial. Journal of Clinical Oncology ·Sandra P. D’Angelo, Andrew Furness, Fiona Thistlethwaite, Melissa Burgess, Richard F. Riedel, John B.A.G. Haanen, Jonathan Noujaim, A. Chalmers, Antonio López–Pousa, Rashmi Chugh, Lara E. Davis, Édouard Forcade, Mark Agulnik, Dennis Williams, Mary Woessner, Thomas Faitg, P. Villars, Michael J. Nathenson, Elliot Norry, Albiruni Ryan Abdul Razak	2024	9
6	First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study ESMO Open ·Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Duan Guanghai, Natalie Prinzi, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, Anja von Heydebreck, T. Zheng, Paul Nghiem	2024	9
7	High-grade Undifferentiated Pleomorphic Sarcoma Presenting as Acquired Lymphangioma Circumscriptum SKIN The Journal of Cutaneous Medicine ·Pooja H. Rambhia, Sandra P. D’Angelo, 张楚悦	2023	0
8	Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas Cancer Research Communications ·Evan Rosenbaum, Kenneth Seier, Martina Bradić, Ciara M. Kelly, Sujana Movva, Benjamin A. Nacev, Mrinal M. Gounder, Mary Louise Keohan, Viswatej Avutu, Ping Chi, Katherine A. Thornton, Jason E. Chan, Mark A. Dickson, Mark T.A. Donoghue, William D. Tap, Li‐Xuan Qin, Sandra P. D’Angelo	2023	6
9	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study Journal for ImmunoTherapy of Cancer ·Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Jean‐Jacques Grob, Natalie Prinzi, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, Kravchenko I.V., Barbara Ellers‐Lenz, Parantu K. Shah, 宏板垣, Paul Nghiem	2021	80
10	¹⁸F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma Journal of Nuclear Medicine ·Sonia Mahajan, Christopher A. Barker, Audrey Mauguen, Sandra P. D’Angelo, Randy Yeh, Neeta Pandit‐Taskar	2021	2
11	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A02 and Its Association with Clinical Outcome Clinical Cancer Research* ·Evan Rosenbaum, Kenneth Seier, Chaitanya Bandlamudi, Mark A. Dickson, Mrinal M. Gounder, Mary Lou Keohan, Ping Chi, Ciara M. Kelly, Sujana Movva, Benjamin A. Nacev, Jocelyn Grace, Mark T.A. Donoghue, Emily K. Slotkin, Li‐Xuan Qin, Cristina R. Antonescu, William D. Tap, Sandra P. D’Angelo	2020	12
12	Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients Sarcoma ·Jieun Song, Yachao Zhang, Dae‐Hee Kim, Hooman Yarmohammadi, Etay Ziv, 杨继武, Constantinos T. Sofocleous, William D. Tap, Sandra P. D’Angelo, Joseph P. Erinjeri	2020	5
13	Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC) Annals of Oncology ·Sandra P. D’Angelo, Jeffery S. Russell, J.C. Hassel, Célèste Lebbé, Bartosz Chmielowski, Guilherme Rabinowits, Patrick Terheyden, Isaac Brownell, Isabella Zwiener, Marcis Bajars, van der Vloet, Howard L. Kaufman	2017	2
14	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab Clinical Cancer Research ·Sandra P. D’Angelo, Alexander N. Shoushtari, Mary Louise Keohan, Mark A. Dickson, Mrinal M. Gounder, Ping Chi, Jennifer K. Loo, Pierangelo Cifelli, VA Koshy, C. P. Chang, Joseph P. Erinjeri, Mark J. Bluth, Mori Rimon, Howard Streicher, Naoko Takebe, Li‐Xuan Qin, Cristina R. Antonescu, Ronald P. DeMatteo, Richard D. Carvajal, William D. Tap	2016	98
15	Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma Sarcoma ·Alexander N. Shoushtari, Jonathan Landa, Deborah Kuk, Alejandro Sánchez, George L Hatch, Joel B. Ayers, Chizimuzo T.C. Okoli, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Mary Louise Keohan, Aimeé M. Crago, William D. Tap, Sandra P. D’Angelo	2016	11
16	Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma Annals of Oncology ·Mark A. Dickson, M. R. Mahoney, William D. Tap, Sandra P. D’Angelo, Mary Louise Keohan, Brian A. Van Tine, Mark Agulnik, Laura E. Horvath, Jayasree S. Nair, Gary K. Schwartz	2016	90
17	Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A02+ patients with synovial sarcoma (NCT01343043) Annals of Oncology* ·Crystal L. Mackall, Sandra P. D’Angelo, Stephan A. Grupp, John Glod, Mihaela Druta, Warren Chow, Kevin Chagin, Mark F. Mehler, Gabor Kari, Trupti Trivedi, Tom Holdich, Lini Pandite, Rafael G. Amado	2016	2
18	Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma Journal of Clinical Oncology ·Mark A. Dickson, William D. Tap, Mary Louise Keohan, Sandra P. D’Angelo, Mrinal M. Gounder, Cristina R. Antonescu, Jonathan Landa, Li‐Xuan Qin, Seungjae Son, Mercedes M. Condy, Yelena Ustoyev, Aimeé M. Crago, Samuel Singer, Gary K. Schwartz	2013	317
19	Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers Clinical Cancer Research ·Snjezana Doğan, Ronglai Shen, Daphne Ang, Melissa L. Johnson, Sandra P. D’Angelo, Paul K. Paik, Edyta B. Brzostowski, Gregory J. Riely, Mark G. Kris, Maureen F. Zakowski, Marc Ladanyi Hit paper breakdown →	2012	493
20	Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Journal of Thoracic Oncology ·Yelena Y. Janjigian, Bernard J. Park, Maureen F. Zakowski, Marc Ladanyi, William Pao, Sandra P. D’Angelo, Mark G. Kris, Ronglai Shen, Junting Zheng, Christopher G. Azzoli	2010	101

About Sandra P. D’Angelo

Sandra P. D’Angelo is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Gastroenterology, Immunology and Cardiology and Cardiovascular Medicine, having authored 191 papers that have together received 7.8k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (71 papers), CAR-T cell therapy research (63 papers), Immunotherapy and Immune Responses (40 papers), Cancer Immunotherapy and Biomarkers (37 papers), Polyomavirus and related diseases (30 papers), Vascular Tumors and Angiosarcomas (25 papers), Cardiac tumors and thrombi (22 papers) and Bacteriophages and microbial interactions (18 papers). The work is most often cited by research in Oncology (5.9k citations), Pulmonary and Respiratory Medicine (3.5k citations), Immunology (1.4k citations), Gastroenterology (232 citations) and Pathology and Forensic Medicine (740 citations). Sandra P. D’Angelo has collaborated with scholars based in United States, France and Germany. Frequent co-authors include William D. Tap, Mark A. Dickson, Gary K. Schwartz, Cristina R. Antonescu, Richard D. Carvajal, Mark G. Kris, Célèste Lebbé, Mary Louise Keohan, Mrinal M. Gounder and Patrick Terheyden. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal for ImmunoTherapy of Cancer, Clinical Cancer Research and American Society of Clinical Oncology Educational Book.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact